|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Considering that chronic obesity decreases ArcN NPY content, we propose that the ArcN NPY neuropathway to the PVN and DMH is pivotal in obesity-induced elevations in SNA.
|
28628036 |
2017 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Logistic regression analysis did not reveal significant association with obesity and NPY single-nucleotide polymorphisms (SNPs) in the present study.
|
20531438 |
2010 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The objectives of this study were to compare Y5R mRNA and adipocyte parameters consisting of area, width, height, and perimeter either between obese and non-obese subjects or between subcutaneous and visceral fat as well as to compare between NPY, Y1R, Y2R, and Y5R mRNA expressions in subcutaneous and visceral adipose tissues.
|
29763369 |
2018 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, upregulation of NPY may have an impact in anti-cancer treatment of neuroblastomas with VPA, and antagonizing hypothalamic NPY effects may help to ameliorate VPA-induced weight gain and obesity without interfering with the desired central effects of VPA.
|
23994577 |
2013 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study.
|
18043699 |
2009 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Polymorphisms in the ghrelin (GHRL) and neuropeptide Y (NPY) genes were examined in the same population-based case-control study of NHL to further explore the role of genes involved in energy homeostasis and obesity in susceptibility to NHL.
|
15894681 |
2005 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The objective was to examine the effects of NPY variant rs16147 on central obesity and abdominal fat distribution in response to dietary interventions.
|
26156739 |
2015 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our findings show that life-long tonic repression of NPY system with a stable increase in leptin availability in the hypothalamus prevented the age-related and high fat-diet-induced obesity, hyperinsulinemia and diabetes and extended lifespan.
|
17979776 |
2007 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Few genes such as leptin, leptin receptor encoded by the db (diabetes), pro-opiomelanocortin, AgRP and NPY and melanocortin-4 receptors and insulin-induced gene 2 were linked to obesity.
|
27623943 |
2016 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
One of these, a cytosine to thymine (C-->T) substitution in the untranslated region between the genes for NPY Y1 and Y5 (allele frequency 0.11), was significantly associated with both lower fasting triglyceride level (152 vs 125 mg/dl), and higher high-density lipoprotein (HDL) concentrations (49 vs 45 mg/dl) (p < 0.01) in 306 obese subjects.
|
12220433 |
2002 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
These findings suggest that PTX3 plays a key role in the development of obesity by enhancing adipocyte differentiation and lipid synthesis <i>via</i> NPY/NPYR signaling.
|
30105036 |
2018 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The present study examined the neuropeptide-Y Y1 receptor gene (NPYY1R) for involvement in essential hypertension (HT) and obesity.
|
7902088 |
1993 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The Role of Neuropeptide Y and Peptide YY in the Development of Obesity via Gut-brain Axis.
|
30678628 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
NPY deficiency attenuates the obesity syndrome of mice deficient for leptin (ob/ob), but these effects are not mediated by NPY signaling through the Y5R because Y5R-null ob/ob mice are equally obese.
|
9623983 |
1998 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here, we sought to determine whether the effects of NPY on feeding and/or obesity are dissociable from effects on hepatic VLDL-TG secretion.
|
23074243 |
2012 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
In addition, moderate down-regulation of NPY did not affect basal feeding or normal body weight gain but the response to food deprivation was compromised since fasting-induced hyperphagia was inhibited and fasting-induced decrease in locomotor activity was absent.These results highlight the importance of the physiological ARC NPY levels oscillations on feeding regulation, fasting response and body weight preservation, and are important for the design of therapeutic interventions for obesity that include the NPY.
|
21799827 |
2011 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The neuropeptide Y system affects various processes, among others food intake, and is frequently discussed in the context of targeting obesity.
|
31533726 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Two complementary genetic approaches were used: 1) linkage analyses between obesity and polymorphic markers located nearby NPY and rNPY-Y1/-Y5 genes (respectively on chromosomes 7p15.1 and 4q[31.3-32]) in 93 French Caucasian morbidly obese families; 2) single strand conformation polymorphism (SSCP) scanning of the coding region of the NPY and rNPY-Y1 genes performed in 50 unrelated obese patients ascertained on the basis of a body mass index of 27 kg/m2 or more and a family history of obesity.
|
9222646 |
1997 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Mechanistically, it is the diminished insulin signaling capacity on central amygdala NPY neurons under combined stress and high-fat-diet conditions that leads to the exaggerated development of obesity.
|
31031093 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Neuropeptide Y (NPY) is a neurotransmitter and enhances the development of obesity and other aspects of MetS.
|
22308535 |
2013 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Several studies have shown that obesity is associated with increased levels of NPY in the hypothalamus.
|
28954935 |
2018 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the mechanism of the effect of topiramate to create a state of obesity is thought to involve the decrease in the levels of NPY and FTO.
|
28914170 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Neuropeptide Y (NPY) is a sympathetic neurotransmitter that has been implicated in various disorders including obesity, gastrointestinal and cardiovascular diseases.
|
29370406 |
2018 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
To identify NPY gene-by-stress interaction effects on human obesity, we analyzed the interaction between four NPY SNPs and stress with obesity-related traits, including visceral adipose tissue (VAT).
|
27010740 |
2016 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
These studies underscore the potential of (pGlu-Gln)-CCK-8 for the treatment of obesity-diabetes and suggest modulation of NPY and melanocortin related pathways may be involved in the observed beneficial effects.
|
23315994 |
2013 |